Ovarian Cancer Research Alliance Community Partner

RSS News

  • Lynparza Combo Recommended by EU Committee as First-line Maintenance for Advanced Ovarian Cancer September 24, 2020
    Lynparza (olaparib), in combination with bevacizumab, has been recommended for approval in the European Union (EU) as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who responded to platinum-based chemotherapy. The positive opinion released by the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, also includes […]
  • CHMP Favors Zejula as First-line Maintenance Therapy for Platinum-sensitive Advanced Ovarian Cancer September 22, 2020
    The Committee for Medicinal Products for Human Use (CHMP) has recommended Zejula (niraparib) as a first-line maintenance therapy for women with advanced ovarian cancer who responded to platinum-based chemotherapy. This favorable opinion by the committee, a branch of the European Medicines Agency (EMA), is one of the final steps of Zejula’s marketing authorization procedure that may lead to […]
  • Checkpoint Inhibitor CTX-2026 Shows Promising Efficacy in Preclinical Study September 17, 2020
    Compass Therapeutics‘ CTX-2026, an antibody targeting the protein BTN3A1, could be therapeutic in ovarian cancer by helping the immune system destroy cancer cells, preclinical data show. The study, “BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells,” was published in the journal Science. The body’s immune system is responsible for fighting off infections […]
  • Newk’s Cares Honors Late Co-founder Lori Newcomb During Awareness Month September 15, 2020
    Newk’s Cares is honoring the legacy of co-founder Lori Newcomb this September during Ovarian Cancer Awareness Month with fundraising initiatives online and at the more than 100 Newk’s Eatery restaurants. Newk’s Cares is the philanthropic arm of Newk’s Eatery, the Jackson, Mississippi-based fast-casual restaurant chain. It was established in 2014, a year after Newcomb, an […]
  • Pap Smear Samples May Aid Early Diagnosis of Common Ovarian Cancer September 10, 2020
    Genetic material collected in routine cervical cancer screenings could be used to screen for ovarian cancer several years before disease symptoms are evident, possible speeding diagnosis and treatment, a study suggests. The study, “Detection of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis,” was […]
  • National Ovarian Cancer Coalition Readies ‘Together in Teal’ Virtual Fundraiser September 8, 2020
    The National Ovarian Cancer Coalition (NOCC) is hosting its annual Together in Teal — No Boundaries fundraiser as a nationwide virtual celebration on Sept. 26, it announced in a press release. Presented during National Ovarian Cancer Awareness Month, the event raises money to support early disease awareness, quality of life for survivors, scientific research, and community […]
  • Research Alliance Hopes to Raise $200K During Awareness Month September 3, 2020
    The Ovarian Cancer Research Alliance (OCRA) is hoping to raise $200,000 in this year’s awareness month campaign to help fund research and support those with the disease, the organization announced. OCRA, the largest non-government funder of ovarian cancer research, is urging people worldwide to make single or monthly donations, which can be dedicated in memory […]
  • Organ-on-a-chip Device Shows How Cancer Cells Interact With Platelets to Drive Metastasis September 1, 2020
    To communicate with platelets and start the process of cancer spread, ovarian cancer cells are able to break the barriers of blood vessels and let platelets inside the tumor environment, according to a study that used microfluidic organ-in-a-chip technology. Atorvastatin, a medication belonging to cholesterol-lowering statins, is able to maintain blood vessel integrity and prevent […]
  • First Ovarian Cancer Patients Dosed in Phase 2 of OVATION 2 Trial August 27, 2020
    The first two patients have been randomized in Phase 2 of the OVATION 2 trial testing the immunotherapy candidate GEN-1 in newly diagnosed advanced ovarian cancer. Celsion Corporation, the immunotherapy’s developer, expects to enroll up to 118 patients in this second part of the study by the end of 2021, and will provide clinical updates throughout the […]
  • Large-scale Testing of BRCA Mutations Can Be Cost-Effective, Study Finds August 18, 2020
    Screening the overall population for mutations in the genes BRCA1 and BRCA2 that can cause breast and ovarian cancer is cost-effective in wealthier countries, from the viewpoint of both payers and society, an economic analysis study suggests. But these screenings are still too expensive to be cost-effective in less wealthy countries under such an analysis. “We must invest […]
  • XMT-1536 on FDA Fast Track for Platinum-resistant, Advanced Ovarian Cancer August 13, 2020
    The U.S. Food and Drug Administration (FDA) has given  fast track designation to Mersana Therapeutics’ XMT-1536 as a possible treatment for women with platinum-resistant high-grade serous ovarian cancer who received up to three prior lines of therapy. The designation also covers those who were treated with four different systemic therapies, regardless of their platinum-disease status. Fast track is meant to […]
  • Partnership Improves Patient Access to Apealea Outside US August 11, 2020
    Elevar Therapeutics and Tanner Pharma Group have partnered to make Apealea (paclitaxel micellar) accessible in areas outside the U.S. where the medication is not available. The companies have created a global named patient program, also known as an early or expanded access program, which provides physicians with a framework to legally and ethically prescribe investigational […]
  • Study: Tests Used to Predict Response to PARP Inhibitors Yield Inconsistent Result August 4, 2020
    Tests used in clinical trials of ovarian cancer to determine if tumors lack the ability to repair their DNA — a status termed “homologous recombination deficiency” (HRD), and likely would respond to treatment with PARP inhibitors — yield inconsistent results, a recent study shows. Study findings were presented in the poster “Comparison of genomic instability test […]
  • Liposomal Doxorubicin-based Regimen Improves Outcomes in Platinum-sensitive Ovarian Cancer July 30, 2020
    Second-line treatment with a combination of bevacizumab plus the chemotherapies carboplatin and pegylated liposomal doxorubicin may significantly improve the outcomes of platinum-sensitive ovarian cancer patients, compared to standard treatment, findings from a Phase 3 trial suggest. Women who received this experimental combination in the ENGOT-ov18 trial (NCT01837251) lived significantly longer without disease progression and experienced […]
  • Pamiparib Granted Priority Review in China for Treatment of Advanced Ovarian Cancer July 28, 2020
    China’s regulatory agency has granted priority review status to BeiGene‘s new drug application (NDA) requesting the approval of pamiparib, its investigational PARP inhibitor, for the treatment of advanced ovarian cancers. Priority review is granted in China to reduce the time to review and approve promising therapies that address urgent clinical needs. The NDA specifically covers patients with advanced ovarian, fallopian […]